SUDEEP PHARMA LIMITED reported revenue of ₹158 cr and net profit of ₹40.55 cr in Q1 FY27 (quarter ended 30 Jun 2026), +31.6% year on year. Below is the full quarter-wise results table with revenue, operating profit, margins, tax, EPS and annual history — updated automatically from exchange filings.
SUDEEP PHARMA LIMITED (SUDEEPPHRM) has reported its Q1 FY27 results for the quarter ended 2026-06-30. The company posted revenue of ₹158 cr and a net profit of ₹40.55 cr, translating into earnings per share of ₹3.59.
Compared with the same quarter a year earlier, revenue grew strongly by +26.7% and net profit grew strongly by +31.6%. Profit rising faster than revenue points to better cost control or operating leverage flowing through the P&L.
Operating profit for the quarter stood at ₹50.91 cr, an operating margin of 32.2% versus 32.5% a year ago — a contraction of 0.4 percentage points.
SUDEEPPHRM quarter-wise results table
Revenue
₹158 cr
+26.7%YoY
Net profit
₹40.55 cr
+31.6%YoY
Operating profit
₹50.91 cr
+25.3%YoY
EPS
₹3.59
+31.6%YoY
SUDEEP PHARMA LIMITED (SUDEEPPHRM) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth
Quarter
Revenue
Operating profit
Net profit
OPM
Net margin
EPS
Profit YoY
Profit QoQ
Q1 FY272026-06-30
₹158 cr
₹50.91 cr
₹40.55 cr
32.2%
25.6%
₹3.59
+31.6%
-17.0%
Q4 FY262026-03-31
₹182 cr
₹58.71 cr
₹48.88 cr
32.2%
26.8%
—
+10.6%
+3.0%
Q3 FY262025-12-31
₹172 cr
₹56.11 cr
₹47.46 cr
32.6%
27.5%
₹4.29
—
+54.1%
Q1 FY262025-06-30
₹125 cr
₹40.62 cr
₹30.81 cr
32.5%
24.7%
₹2.73
—
-30.3%
Q4 FY252025-03-31
₹158 cr
₹55.95 cr
₹44.19 cr
35.5%
28.0%
—
—
—
TTM (last 4 quarters)
₹638 cr
₹206 cr
₹168 cr
32.4%
26.3%
—
—
—
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
SUDEEPPHRM quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
SUDEEP PHARMA LIMITED quarterly income statement
Particulars
Q1 FY272026-06-30
Q4 FY262026-03-31
Q3 FY262025-12-31
Q1 FY262025-06-30
Q4 FY252025-03-31
Revenue / Sales
₹158 cr
₹182 cr
₹172 cr
₹125 cr
₹158 cr
Total expenses
₹107 cr
₹124 cr
₹116 cr
₹84.29 cr
₹102 cr
Gross profit
₹102 cr
₹118 cr
₹112 cr
₹82.6 cr
₹97.78 cr
Operating profit (EBIT)
₹50.91 cr
₹58.71 cr
₹56.11 cr
₹40.62 cr
₹55.95 cr
Operating margin
32.2%
32.2%
32.6%
32.5%
35.5%
Interest cost
₹2.06 cr
₹2.44 cr
₹1.17 cr
₹1.71 cr
₹1.85 cr
Profit before tax
₹54.29 cr
₹62.69 cr
₹61.78 cr
₹44.07 cr
₹57.85 cr
Tax expense
₹13.71 cr
₹14.15 cr
₹14.08 cr
₹12.8 cr
₹13.67 cr
Effective tax rate
25.2%
22.6%
22.8%
29.0%
23.6%
Net profit (PAT)
₹40.55 cr
₹48.88 cr
₹47.46 cr
₹30.81 cr
₹44.19 cr
Net profit margin
25.6%
26.8%
27.5%
24.7%
28.0%
Basic EPS
₹3.59
—
₹4.29
₹2.73
—
Diluted EPS
₹3.59
—
₹4.29
₹2.73
—
SUDEEPPHRM results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter
Growth
Q1 FY27
Q4 FY26
Q3 FY26
Q1 FY26
Q4 FY25
Revenue YoY
+26.7%
+15.7%
—
—
—
Revenue QoQ
-13.2%
+5.8%
+38.0%
-20.7%
—
Operating profit YoY
+25.3%
+4.9%
—
—
—
Operating profit QoQ
-13.3%
+4.6%
+38.1%
-27.4%
—
Net profit YoY
+31.6%
+10.6%
—
—
—
Net profit QoQ
-17.0%
+3.0%
+54.1%
-30.3%
—
EPS YoY
+31.6%
—
—
—
—
EPS QoQ
—
—
+57.3%
—
—
SUDEEPPHRM annual results history
Full-year performance for SUDEEP PHARMA LIMITED, useful for reading each quarter in context.
SUDEEP PHARMA LIMITED annual income statement
Particulars
FY262026-03-31
FY252025-03-31
FY242024-03-31
FY232023-03-31
Revenue / Sales
₹639 cr
₹497 cr
₹455 cr
₹426 cr
Total expenses
₹430 cr
₹316 cr
₹280 cr
₹342 cr
Gross profit
₹403 cr
₹325 cr
₹282 cr
₹237 cr
Operating profit (EBIT)
₹208 cr
₹181 cr
₹174 cr
₹83.93 cr
Operating margin
32.6%
36.4%
38.3%
19.7%
Interest cost
₹5.44 cr
₹4.66 cr
₹3.07 cr
₹3.41 cr
Profit before tax
₹228 cr
₹183 cr
₹175 cr
₹85.98 cr
Tax expense
₹53.79 cr
₹44.12 cr
₹41.63 cr
₹23.66 cr
Effective tax rate
23.6%
24.1%
23.8%
27.5%
Net profit (PAT)
₹173 cr
₹139 cr
₹133 cr
₹62.32 cr
Net profit margin
27.1%
27.9%
29.3%
14.6%
Basic EPS
₹15.50
₹12.28
₹11.79
₹5.52
Diluted EPS
₹15.50
₹12.28
₹11.79
₹5.52
Revenue trend and demand read-through
Topline for Q1 FY27 came in at ₹158 cr against ₹125 cr in Q1 FY26, and ₹182 cr in the preceding Q4 FY26 quarter.
On a sequential basis revenue declined -13.2%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹107 cr, or 67.8% of revenue, with operating profit grew +25.3% year on year.
Margins, tax and profitability
Net profit of ₹40.55 cr works out to a net margin of 25.6% compared with 24.7% in the year-ago quarter. Margin expansion of this kind usually reflects a better product or service mix, softer input costs, or tighter overheads.
Below the operating line, SUDEEP PHARMA LIMITED reported profit before tax of ₹54.29 cr, a tax charge of ₹13.71 cr (effective rate 25.2%), interest cost of ₹2.06 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹48.88 cr in Q4 FY26 to ₹40.55 cr in Q1 FY27, a change of -17.0%.
Trailing twelve months and annual context
Across the trailing four quarters SUDEEP PHARMA LIMITED has generated revenue of ₹638 cr and net profit of ₹168 cr, a trailing net margin of 26.3%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹639 cr with net profit of ₹173 cr and EPS of ₹15.50, versus the prior year where revenue grew +28.4% and profit grew +24.6%.
What to watch in the next SUDEEPPHRM quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A sustained run of year-on-year profit growth is what usually drives a re-rating rather than any single quarter.
SUDEEP PHARMA LIMITED has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
SUDEEPPHRM results coverage
No results report published for SUDEEPPHRM yet — our desk covers each quarter within minutes of the filing.
What were SUDEEP PHARMA LIMITED (SUDEEPPHRM) Q1 FY27 results?
In Q1 FY27 (quarter ended 30 Jun 2026), SUDEEP PHARMA LIMITED reported revenue of ₹158 cr and net profit of ₹40.55 cr, a change of +31.6% year on year on +26.7% revenue growth. EPS stood at ₹3.59.
What is SUDEEPPHRM profit margin in Q1 FY27?
SUDEEP PHARMA LIMITED posted a net profit margin of 25.6% and an operating margin of 32.2% in Q1 FY27. On a trailing twelve-month basis, revenue is ₹638 cr and net profit ₹168 cr.
Did SUDEEPPHRM results beat the previous quarter?
SUDEEP PHARMA LIMITED net profit changed -17.0% quarter on quarter, from ₹48.88 cr in Q4 FY26 to ₹40.55 cr in Q1 FY27.
When are SUDEEP PHARMA LIMITED (SUDEEPPHRM) quarterly results?
SUDEEP PHARMA LIMITED has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Where can I see SUDEEPPHRM latest quarterly results?
Results coverage for SUDEEPPHRM will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the SUDEEPPHRM stock page.
What is SUDEEP PHARMA LIMITED annual revenue and profit?
For FY26, SUDEEP PHARMA LIMITED reported full-year revenue of ₹639 cr and net profit of ₹173 cr, with EPS of ₹15.50.
How many quarterly results has SUDEEPPHRM declared recently?
Past results dates for SUDEEPPHRM will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 12 Sept 2026. For information only, not investment advice.